

Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens

Christopher E. Jensen,^{1,2} Hilary M. Heiling,^{2,3} Konan E. Beke,¹ Allison M. Deal,³ Ashley L. Bryant,^{3,4} Lorinda A. Coombs,^{3,4} Matthew C. Foster^{1,3} and Daniel R. Richardson^{1,3}

¹University of North Carolina School of Medicine; ²University of North Carolina Gillings School of Global Public Health; ³Lineberger Comprehensive Cancer Center, University of North Carolina and ⁴University of North Carolina School of Nursing, Chapel Hill, NC, USA

Correspondence: D.R. Richardson
daniel_richardson@med.unc.edu

Received: January 21, 2022.

Accepted: June 10, 2022.

Early view: July 21, 2022.

<https://doi.org/10.3324/haematol.2022.280728>

©2023 Ferrata Storti Foundation

Published under a CC BY-NC license



Appendix: Supplementary data

Table S1. Best response to therapy, stratified by first-line treatment

Response	AZA monotherapy - N (%)	AZA+VEN - N (%)	VEN + Other medication - N (%)
CR	4 (9.5%)	21 (37.5%)	0 (0.0%)
CRi	0 (0.0%)	5 (8.9%)	0 (0.0%)
MLFS	0 (0.0%)	7 (12.5%)	1 (9.1%)
No remission	38 (90.5%)	23 (41.1%)	10 (90.9%)
Composite remission*	4 (9.5%)	33 (58.9%)	1 (9.1%)

AZA: Azacitidine, VEN: Venetoclax, CR: complete response, CRi: complete response with incomplete hematologic recovery, MLFS: morphologic leukemia-free state. 4 individuals could not be assigned a best response due to missing data. Fisher's exact test p value for differences in response types by therapy group <0.001.

*Composite complete remission defined as achieving CR, CRi, or MLFS.

Table S2. Median survival in months, stratified by therapy group and by best response

	Median OS (95% CI) - Months
Therapy group	
AZA monotherapy	7.6 (2.8-13.3)
AZA+VEN	9.1 (3.4-11.9)
VEN+ Other medication	4.1 (2.0-9.6)
Best response	
CR	26.4 (9.8- .)
CRi	. (2.9- .)
MLFS	6.1 (2.2- .)
No remission	3.2 (2.4-4.9)

AZA: Azacitidine, VEN: Venetoclax, CR: complete response, CRi: complete response with incomplete hematologic recovery, MLFS: morphologic leukemia-free state. 4 individuals could not be assigned a best response due to missing data. Periods indicate values that could not be calculated due to small cell sizes.

Table S3. Proportion of person-days spent in various locations, stratified by first-line therapy among recipients of azacitidine

Variable	Unadjusted Mean (95% CI)	Adjusted Mean*	p[†]
Proportion of days at home (PDH)			
AZA monotherapy (n=44)	0.57 (0.49, 0.66)	0.70	(referent)
AZA+VEN (n=58)	0.60 (0.54, 0.66)	0.72	0.6421
Proportion of days not at home (1-PDH)			
AZA monotherapy	0.43 (0.34, 0.51)	0.30	(referent)
AZA+VEN	0.40 (0.34, 0.46)	0.28	0.6421
Proportion of days inpatient			
AZA monotherapy	0.26 (0.16, 0.35)	0.11	(referent)
AZA+VEN	0.20 (0.14, 0.25)	0.07	0.2192
Proportion of days seen as outpatient			
AZA monotherapy	0.16 (0.13, 0.20)	0.18	(referent)
AZA+VEN	0.18 (0.15, 0.21)	0.19	0.4874

AZA: Azacitidine, VEN: Venetoclax. Emergency department visits were excluded from these models due to the large number of individuals with zero visits.

* Means are adjusted for the log of length of follow up.

† p values compare adjusted means and are calculated via Wald's chi square.